Directorio

We are doing this study to compare the usual treatment with hormonal therapy medications to treatment with low-dose tamoxifen. We want to know which option has better outcomes for people with low-risk early-stage breast cancer.

We are doing this study to compare the standard treatments (FOLFOX or CAPOX after chemoradiation) for rectal cancer to a drug regimen called FOLFIRINOX that is given after chemoradiation. We want to know if FOLFIRINOX after chemoradiation can provide better outcomes than either of the 2 standard treatments.

We are doing this study to find out if using Radium-223 dichloride (the study drug) in combination with cabozantinib is a safe and effective treatment for advanced RCC that has spread to the bone. We want to know if this combination is potentially better than the standard treatment of cabozantinib on its own.

We are doing this study to compare two different treatment options for mantle cell lymphoma. We want to find out which option has the best outcomes for older adults. We will compare the results of continuous treatment with zanubritinib to treatment with zanubrutinib that is stopped after the initial six 28-day cycles of chemotherapy and restarted only if your disease gets worse following the initial six 28-day cycles of chemotherapy.

We are doing this study to see if combining immunotherapy with chemotherapy is a better treatment than chemotherapy alone for NSCLC.

We are doing this study to help create a national biobank of samples and data about patients who experience side effects when they take immunotherapy drugs for their cancer. We want to find out why some people experience side effects and why others do not. We also want to learn more about how to diagnose and treat these side effects more effectively.

We are doing this study to test a new strategy to help people quit smoking. We want to know if the study approach is better than the usual approach. The usual approach is to encourage patients to quit smoking using cessation support manuals and either medication or nicotine replacement products. We want to know if the study approach works better for cancer survivors who live in rural areas.

We are doing this study to find out if an experimental gene therapy drug called ABBV-RGX-314 (the study drug) has similar effects to approved drugs, such as Lucentis® or Eylea® injections. The study drug will be injected into one eye with a Suprachoroidal Space (SCS) Microinjector®, which is an investigational needle device developed by Clearside Biomedical, Inc.